Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 25 microgram - tablet - excipient ingredients: purified talc; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; azelastine hydrochloride, quantity: 137 microgram/actuation (equivalent: azelastine, qty 125 microgram/actuation) - spray, nasal - excipient ingredients: glycerol; disodium edetate; phenethyl alcohol; purified water; carmellose sodium; microcrystalline cellulose; polysorbate 80; benzalkonium chloride - symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; azelastine hydrochloride, quantity: 137 microgram/actuation (equivalent: azelastine, qty 125 microgram/actuation) - spray, nasal - excipient ingredients: disodium edetate; purified water; glycerol; microcrystalline cellulose; polysorbate 80; phenethyl alcohol; benzalkonium chloride; carmellose sodium - symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - ciclesonide, quantity: 50 microgram/actuation - spray, nasal - excipient ingredients: potassium sorbate; hypromellose; purified water; microcrystalline cellulose; disodium edetate; carmellose sodium; hydrochloric acid; nitrogen - omnaris nasal spray is indicated for: the treatment of seasonal allergic rhinitis in adults and children 6 years of age and older; and for the treatment of perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - dutasteride, quantity: 500 microgram; tamsulosin hydrochloride, quantity: 400 microgram - capsule, modified release - excipient ingredients: maize starch; carrageenan; gelatin; purified talc; butylated hydroxytoluene; iron oxide yellow; titanium dioxide; iron oxide red; glycerol; medium chain triglycerides; potassium chloride; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); purified water; triethyl citrate; lecithin; glyceryl caprylate/caprate; sunset yellow fcf; carnauba wax; hypromellose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - duodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (bph).

United States - English - NLM (National Library of Medicine)

penleigh irving ltd - microcrystalline wax (unii: xof597q3ky) (microcrystalline wax - unii:xof597q3ky), rosin (unii: 88s87kl877) (rosin - unii:88s87kl877), turpentine (unii: xj6ruh0o4g) (turpentine - unii:xj6ruh0o4g), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - microcrystalline wax 103.31 g in 147 g

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: quinoline yellow; purified talc; polyethylene oxide; cochineal; microcrystalline cellulose; magnesium stearate; hyprolose; butylated hydroxytoluene; macrogol 400; titanium dioxide; iron oxide black; hypromellose; colloidal anhydrous silica - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 0.6248 mg (equivalent: fentanyl, qty 400 microgram) - tablet - excipient ingredients: mannitol; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 0.3142 mg (equivalent: fentanyl, qty 200 microgram) - tablet - excipient ingredients: mannitol; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 0.1571 mg (equivalent: fentanyl, qty 100 microgram) - tablet - excipient ingredients: mannitol; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.